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(57) ABSTRACT
A method for delivering therapeutic radiation to a target
includes positioning a multi-aperture collimator on the skin
within a trajectory of orthovoltage x-rays directed at the
target, thus generating an array ofminibeams, each of width
between 0.1 mm to 0.6 mm. The skin is irradiated with the
array. An effective beam of therapeutic radiation, which may
be a solid beam,is deliveredto the target at a predetermined
tissue depth by merging adjacent orthovoltage x-ray mini-
beamssufficiently to form the effective beam. The effective
beam may be formed proximal to the target. The depth at
which the effective, preferably, solid, beam is formed is
controlled by varying one or more of the spacing of the
minibeams in the array, the minibeam width, the distance
from the x-ray source to the collimator, and the x-ray source
spot size. Planar minibeams can be arc-scanned while con-
tinuously modulating beam shape andintensity.
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This application claims the benefit of and priority to U.S.
Provisional Application Ser. No. 62/201,247, filed Aug. 5,
2015, entitled “Orthovoltage X-Ray Collimator and Radia-
tion Therapy Utilizing Same,” U.S. Provisional Application
Ser. No. 62/210,623, filed Aug. 27, 2015, entitled “Ortho-
voltage X-Ray Minibeams: Radiation Therapy With Smaller
Impact on Non-targeted Tissues,” and U.S. Provisional
Application Ser. No. 62/311,325, filed Mar. 21, 2016,
entitled “Arc-Scan Intensity-Modulated Radiation Therapy
Using Orthovoltage X-Ray Minibeams,”the entirety of each
of which is hereby incorporated herein by reference thereto.
FIELD OF THE DISCLOSURE
The present disclosure relates to methods and systems for
performing radiation therapy using orthovoltage x-rays for
treating tumors, including brain tumors, and for treating
neurological disorders such as epilepsy.
BACKGROUND
Radiation therapy, which is one of three main methods of
treating cancer, together with surgery and chemotherapy,is
currently carried out predominantly with high energy x-rays
of one to several MeV energy produced by special x-ray
generators employing electron linear accelerators (“‘linacs’’)
of several MV high voltage. MeV x-rays have good attri-
butes for use in radiation therapy, in particular, high tissue
penetration and a robust sparing ofthe first few millimeters
of shallow tissues, generally known as a “skin-sparing
effect.” They also have several shortcomings, most signifi-
cantly, the normal, non-targeted tissue that is located proxi-
mal, distal, and lateral to the target receive excessive radia-
tion damage as described further herein.
This is because the modeofinteraction of the high energy
x-rays that are produced, typically 1-4 MeV, is Compton
scattering and not photoelectric. As a result, the dose dis-
tribution produced in a patient’s body is mostly from mul-
tiple Compton scattering from a wide range of angles and,
therefore, is not well-confined within the target.
In particular, the doses produced at the target tissue by
MV sources do not sharply fall at the target’s edge. Instead,
the dose distribution at the target’s edge is rather blunt-
edged. Quantitatively, the so-called “80%-to-20% dose fall-
off’ producedat the target by high energy x-rays is typically
2-5 mm. In addition, the beam-shaping collimators, so-
called “multi-leaf collimators,” required to produce the
high-energy beam profiles, consist of heavy, thick “leaves”
which do not lend themselves to production of fine exposure
profiles. Because these collimators fail to produce beam-
exposure profiles with fine contours, unnecessary radiation
dose is delivered to normal tissues, especially when small
targets are exposed. Such large falloffs result in unnecessary
and undesirable dose being delivered to the tissues located
in the immediate neighborhoodofthe target.
Further, because high energy x-rays have little preferen-
tial absorption in heavier elements compared to the light
elements that constitute most of the tissues, the concept of
tumor-dose enhancement by the introduction of contrast
agents to the tumor such as iodine and gold cannot be






energy x-rays. In addition, although the large penetration of
the dose from high-energy x-rays to tissue depths is con-
sidered an advantage for thick targets, for thin tumors the
shallow dose falloff of the high energy x-rays with depth is
a negative effect, allowing the exposure to high radiation
dose of all tissues positioned distal to the target. FIG. 1
illustrates dose penetration 10 in tissues for different high-
energy MeV x-ray beams 12, comparedto the dose penetra-
tion curve for an orthovoltage tube 14.
Before MV x-ray machines were developed (around the
mid-20th century), x-ray generators of lower energy, called
“orthovoltage” x-ray machinesor tubes were usedfor radia-
tion therapy. The acceleration voltage of these early x-ray
machines wasrather small, mostly up to 250 kVp, producing
x-rays with a median energy, or mean energy, of about 110
keV. These beam energies were too low to penetrate deep in
the tissue, and also lacked the beam sparing effect of the
shallow tissues that the high-energy MV x-rays exhibit, in
fact lower than that shownin FIG.1 for orthovoltage x-rays.
Asa result, the skin and the normaltissues proximal to the
target received significant radiation damage. FIG. 1 com-
pares the dose penetration in tissues from high energy x-rays
produced by electron linacs to that from a 300 kVp ortho-
voltage tube filtered moderately, labeled by half-value layer
(HVL) in copper as “3.0 mm Cu HVL.”
To address the damageto healthy skin tissue using ortho-
voltage x-rays, a so-called “grid therapy” was developed.
Conventional grid therapy used a metal or lead grid with
openings of at least 1.0-1.5 cm diameter to ameliorate the
skin damagethat occurredin treating deep tumors. However,
the orthovoltage grid therapy techniquesofferedlittle, if any,
tissue-sparing to healthy subcutaneoustissue proximalto the
target, and thus did not solve the problem of damageto the
normal tissues proximal to deep tumors. Furthermore, no
method or system was contemplated for controlling the
tissue depth at which a therapeutic dose could be produced
across a target by the merging of the beamsexiting the grid.
Accordingly, there is a need for a method and system for
performing radiotherapy using orthovoltage x-rays for effec-
tively treating tumors while sparing both the skin andtissue
proximalto the target. There is also a need for a system and
method for controlling the tissue depth at which a therapeu-
tic dose of orthovoltage x-ray radiation can be delivered to
the target while sparing tissue proximal to the target. The
development of such improved orthovoltage x-ray systems
may provide not only benefit to a wide range ofclinical
applications by reducing dose to the non-targeted tissues, but
also a low-cost and compact solution for performing radio-
therapy to effectively treat tumors, as well as neurological
targets.
SUMMARY
Features of the disclosure will become apparent from the
following detailed description considered in conjunction
with the accompanying drawings. It is to be understood,
however, that the drawings are designed as an illustration
only andnotas a definition of the limits of this disclosure.
The present disclosure relates to a system and method for
effectively treating tumors and neurological targets using
orthovoltage x-ray radiation while sparing both the skin and
irradiated tissue that is proximal to the target. The present
disclosure also relates to a system and method for control-
ling the tissue depth at which a therapeutic dose of ortho-
voltage x-ray radiation can be delivered to the target while
sparing at least a substantial portion of tissue proximal to the
target. Such improved orthovoltage x-ray systems maypro-
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vide a low-cost and compactsolution for performing radio-
therapy to effectively treat tumors, as well as neurological
targets.
The present disclosure also relates to a method for deliv-
ering therapeutic radiation to a target within a subject,
wherein the target is located at a predetermined depth from
an irradiated portion of a surface of the skin of the subject.
The methodincludes positioning a multi-aperture collimator
on or near the surface of the skin within a trajectory of
radiation, which is produced by an x-ray source generating
orthovoltage x-rays, and which is directed at the target. The
multi-aperture collimator is positioned and configured to
generate an array of minibeams on the surface of the skin
comprising slightly diverging spatially distinct minibeams.
Adjacent minibeams formed on the skin have a predeter-
mined center-center spacing, and, preferably, a width of
between about 0.1 mm and about 0.6 mm. The method
further includes irradiating the surface of the skin with the
array of minibeams, and delivering an effective beam of
therapeutic radiation to the target by controlling a tissue
depth at which adjacent orthovoltage x-ray minibeams
merge sufficiently to form the effective beam of therapeutic
radiation.
Tn one aspect, the method further includes controlling the
tissue depth at which the adjacent orthovoltage x-ray mini-
beams merge sufficiently to form the effective beam such
that the effective beam is formed proximalto the target.
The orthovoltage x-ray source may be a focal spot on an
anode of an x-ray tube.
In aspects, controlling the tissue depth at which the
adjacent minibeams mergesufficiently to form the effective
beam includes adjusting at least one of the predetermined
center-to-center spacing, the width, and a distance between
the x-ray source and the multi-aperture collimator.
In various additional aspects, controlling the tissue depth
at which the adjacent minibeams mergesufficiently to form
the effective beam includes adjusting a size of the x-ray
source from which the orthovoltage x-rays are generated.
The tissue depth can be varied, in aspects, from about 1
cm to about 10 cm, based on a predetermined depth of the
target from the surface of the skin.
Controlling the tissue depth may include, in aspects,
selecting the width, the predetermined center-to-center spac-
ing, and the distance between the focal spot and the colli-
mator such that each of the minibeamsbroadento less than
1.0 mm in width before they merge to form the effective
beam of therapeutic radiation, which may be asolid, or
substantially solid, beam of therapeutic radiation.
In aspects, the multi-aperture collimator is a multi-slit
collimator configured with elongated slits such that the array
of minibeams is an array of narrow and elongated planar
minibeams. In some aspects, the width, which corresponds
to a thickness of each planar minibeam, may belimited to a
range of between about 0.25 mm to about 0.35 mm.
The x-ray source, which may be a focal spot formed on
the anodeof an x-ray tube, may have an elongated shape in
embodiments, and aspects of the method may further
include aligning the elongated slits of the multi-slit colli-
mator with the elongated shape of the focal spot.
In yet another aspect, delivering the beam of therapeutic
radiation further includes sparing irradiated tissue proximal
to the target from radiation damage, such that the tissue
depth also correspondsto a tissue sparing depth.
In still other aspects, the method further includes chang-
ing an angular position of the x-ray tube andthe trajectory
of orthovoltage x-rays generated therefrom relative to the







direction, and a different portion ofthe skin 1s irradiated. The
positioning, irradiating and delivering steps are repeated for
the different direction. The multi-aperture collimator is
repositioned for irradiating the different portion of the
surface of the skin while remaining aligned with the trajec-
tory of orthovoltage x-rays for the different direction. The
irradiating step is repeated to irradiate the different portion
of the skin with the array of minibeams generated by the
multi-aperture collimator, and the delivering step is repeated
to deliver the effective beam of therapeutic radiation to the
target from the different direction.
For each angular position, the method, in aspects, also
includes adjusting a beam-shaping collimator and an inten-
sity of the beam to conform the effective beam to a shape of
the target based on the direction of the trajectory relative to
the target.
In still another aspect of the method, the radiating step
includes generating an arc of radiation around the target
from each of the minibeamsin the array. The delivering step
includes merging adjacent arcs of radiation at the tissue
depth to form the effective beam of therapeutic radiation.
In aspects, the minibeamsfor forming the arcs ofradiation
maybe planar minibeams, formed from elongated slits of a
multi-slit collimator, having a length that is greater than the
width, or thickness, of each minibeam.
The arcs of radiation can be generated by rotating the
X-ray source together with the multi-aperture, e.g., a multi-
slit collimator, such that the arcs are generated around the
target in planes parallel to, for example, the elongatedslits
of a multi-slit collimator.
In aspects, while generating the arcs of radiation, the
method further includes continuously adjusting a shape and
an intensity of the beam to conform the effective beam of
therapeutic radiation to a shape of the target based on a
direction from which the beam irradiates the target.
The distance between the multi-aperture collimator and
the x-ray source is also preferably continuously controlled
and adjusted, based on the direction, to maintain the tissue
depth at which the arcs formed from the minibeams merge
to form the beam of therapeutic radiation to be proximal to
the target.
Various aspects of the method may further include admin-
istering dose-enhancing agents to the subject prior to the
irradiating step to radio-sensitize the target. The agents may
be in various forms, including nanoparticles, and may
include one or more of iodine, gadolinium, gold, and plati-
num. In aspects, the agents may be encapsulated in one of
liposomes or polymeric delivery vehicles.
The present disclosure is also directed to a system for
delivering therapeutic radiation to a target volume within a
subject, wherein the target is located at a predetermined
depth measured from anirradiated portion of the skin of the
subject. The system includes an x-ray source generating
orthovoltage x-rays and a multi-aperture collimator. The
multi-aperture collimator is configured for positioning on
the skin within a trajectory of the orthovoltage x-rays
directedat the target. The multi-aperture collimator includes
an array of apertures having a width of between about 0.1
mm and about 0.6 mm and a predetermined center-center
spacing to generate an array of slightly diverging spatially
distinct minibeams of the orthovoltage x-rays at the skin.
The width and the predetermined center-center spacing of
the multi-aperture collimator, a size of the x-ray source, and
a distance between the x-ray source and the collimator are
configured to deliver an effective beam of therapeutic radia-
tion to the target, wherein the beam is formed by sufficient
merging of the minibeams proximalto the target.
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In aspects, the x-ray source is a focal spot on an anode of
an orthovoltage x-ray tube from which orthovoltage x-rays
are generated.
In one aspect, the effective beam of therapeutic radiation
is a solid, or substantially solid, beam of therapeutic radia-
tion. The width, the predetermined center-center spacing, the
size of the x-ray source and the distance are configured to
form the solid beam proximalto the target.
In another aspect, the multi-aperture collimator is remov-
ably interchangeable. The system further includes a set of
multi-aperture collimators configured with predefined aper-
ture widths and shapes and predefined center-center spac-
ings.
In additional aspects, the system may be portable and
configured to be transported on and operated from a mobile
platform.
In aspects, the system further includes a beam-shaping
collimator, positioned in the trajectory of the x-rays and
proximalto the multi-aperture collimator, the beam-shaping
collimator further configured to be adjustable to conform the
effective beam of therapeutic radiation to a shape andsize of
the target.
The system may further include, in various aspects, a
rotatable and translatable gantry on which the orthovoltage
x-ray source, the beam-shaping collimator and the multi-
aperture collimator are mounted, the gantry being positioned
and configured to be rotatable around a horizontal platform
on which a subject being treated is located. The gantry is
configured to position the target in the trajectory of the
orthovoltage x-rays, to tilt around a vertical axis to the
platform to change a direction from which the target is
irradiated with the effective beam of therapeutic radiation,
and to rotate around a longitudinal axis of the horizontal
platform to generate arcs of radiation from each of the
minibeams.
In additional aspects, the system is further configured to
continuously adjust the beam-shaping collimator to conform
the effective beam to the shape andsize of the target based
on the direction of irradiation as the gantry is tilted and
rotated, and to continuously adjust the distance between the
X-ray source and the multi-aperture collimator to maintain
the tissue depth at which the minibeams merge to be
proximalto the target.
In various additional aspects of the system and method of
the present disclosure, the width of the minibeams may be
between about 0.25 mm and about 0.35 mm.
In other aspects of the system and methodofthe present
disclosure, the minibeams may be pencil beams. In yet
another aspect, the array may be a two-dimensional array of
pencil beams.
The pencil beams of the present disclosure, in aspects,
may have a cross-sectional profile that is round, elliptical,
square, rectangular, or of polygonal shape.
In various other aspects of the system and method of the
present disclosure, the multi-aperture collimator may be a
multi-slit collimator configured with elongated slits such
that the array of minibeams is an array of narrow and
elongated planar minibeams.
The collimator may include a multi-aperture or multi-slit
heavy-metal plate.
In various aspects, the width of the apertures, orslits, in
the multi-aperture collimator is between about 0.25 mm and
0.35 mm.
The orthovoltage x-ray tube in various aspects may oper-
ate in a range between about 100 kVp and about 500 kVp.
The present disclosure is also directed to a method for










wherein the target is located at a predetermined depth, and
the predetermined depth is measured from an irradiated
portion of a surface of the skin of the subject. The method
includes positioning a multi-aperture collimator within a
trajectory of orthovoltage x-rays generated by an orthovolt-
age x-ray source. The trajectory of orthovoltage x-rays is
directed at the target. The multi-aperture collimator is posi-
tioned and configured to generate an array of minibeams on
the surface of the skin comprising slightly diverging spa-
tially distinct minibeams having a predetermined width and
a predetermined center-center spacing between adjacent
minibeams.
The method also includes irradiating the surface of the
skin with arcs of radiation formed from the array of mini-
beams, wherein the arcs of radiation are generated around
the target from the minibeamsin the array, and delivering an
effective beam of therapeutic radiation to the target. The
beam is delivered by controlling a tissue depth from the
irradiated surface of the skin at which adjacent arcs of
radiation formed from adjacent minibeams in the array
merge sufficiently to form the effective beam of therapeutic
radiation.
In aspects, the method further includes limiting the width
of the minibeamsto be between about 0.1 mm and about 0.6
mm.
In addition aspects, the minibeams are planar minibeams
formed from elongated slits of a multi-slit collimator. The
arcs of radiation are generated from the minibeams by
rotating the x-ray source together with the multi-slit colli-
mator, such that the arcs are generated around the target in
planes parallel to the elongated slits of the multi-slit colli-
mator.
The method mayfurther include, in aspects, adjusting a
shape andan intensity of the effective beam of therapeutic
radiation to conform to a shape of the target based on a
direction from which the beam irradiates the target.
In further aspects, the method also includes continuously
adjusting the distance between the orthovoltage x-ray source
and the multi-aperture collimator to maintain the tissue
depth at which the minibeams formingthe arcs of radiation
merge to be proximal to the target.
The system and methodsofthe present disclosure may be
applied, in aspects, to delivering a beam, which may, in
additional aspects, be a solid beam,of therapeutic radiation
to a target that encompasses one of a tumor and an epilep-
togenic foci.
In addition to the above aspects of the present disclosure,
additional aspects, objects, features and advantages will be
apparent from the embodiments presented in the following
description and in connection with the accompanying draw-
ings.
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings constitute a part of this disclosure and
include examples, which may be implemented in various
forms. It is to be understood that in some instances, various
aspects of the disclosure may be shown exaggerated or
enlarged to facilitate understanding. The teaching of the
disclosure can be readily understood by considering the
following detailed description in conjunction with the
accompanying drawings.
FIG. 1 is a graphic representation of dose penetration in
water for different radiation sources.
FIG. 2A is a pictorial representation of an embodiment of
a system for practicing a method of the present disclosure.
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FIG.2B is a pictorial representation of an embodiment of
an orthovoltage x-ray device of the present disclosure.
FIG. 2C is a pictorial representation of a portion of an
embodiment of a system for forming a minibeam array of
orthovoltage x-rays of the present disclosure.
FIG. 2D is a pictorial representation of a plate multi-
aperture collimator of the present disclosure.
FIG.3A is a pictorial representation of an embodiment of
a multi-aperture collimator of the present disclosure.
FIG. 3B is a pictorial representation of another embodi-
ment of a multi-aperture collimator of the present disclosure
for forming planar minibeams, which is referred to as a
multi-slit collimator.
FIG. 4A is a block diagram representation of an embodi-
ment of a method of the present embodiment.
FIG. 4B is a block diagram representation of additional
embodiments of a method of the present embodiment.
FIGS. 5A to 5D are graphical representations of dose
profiles, taken perpendicular to an orthovoltage x-ray mini-
beam array formed in accordance with the present disclo-
sure, at incrementally increased depths.
FIGS.6A to 6C are pictorial representations of the imple-
mentation of the system of FIG. 2A to different target depths
in accordance with an embodiment of a method of the
present disclosure.
FIG. 7A is a pictorial representation of the implementa-
tion of the system of FIG. 2A in accordance with another
embodiment of a method of the present disclosure.
FIG. 7B represents a geometry for forming arcs of radia-
tion from an array of orthovoltage x-ray minibeams in
accordance with an embodiment of a method ofthe present
disclosure.
FIG. 7C is a pictorial representation of a gantry for
positioning the system arounda platform on which a subject
is positioned for treatment.
FIGS. 8Ato 8C are pictorial representations of the imple-
mentation of the system of FIG. 2A to different target depths
in accordance with yet another embodimentof a method of
the present disclosure.
FIG. 9 is a graphical representation of the advantage of
filtering an energy spectrum of an orthovoltage x-ray beam
of the present disclosure to increase its median beam energy.
FIG. 10 is a graphical representation of the dose penetra-
tion achieved using orthovoltage x-ray minibeams formed in
accordance with an embodimentof the system and method
of the present disclosure.
FIG. 11 is a graphical representation of the biologically
effective dose as a function of tissue depth before and after
the merging of orthovoltage x-ray minibeams to form an
effective beam of therapeutic radiation in accordance with
the present disclosure.
The various aspects of the present disclosure mentioned
above are described in further detail with reference to the
aforementioned figures and the following detailed descrip-
tion of exemplary embodiments.
DETAILED DESCRIPTION
The following sections describe exemplary embodiments
of the present disclosure. It should be apparent to those
skilled in the art that the described embodiments of the
present disclosure provided herein are illustrative only and
not limiting, having been presented by way of example only.
All features disclosed in this description may be replaced by
alternative features serving the same or similar purpose,
unless expressly stated otherwise. Therefore, numerous









plated as falling within the scopeofthe present disclosure as
defined herein and equivalents thereto.
The present disclosure is directed to a system and method
for using slightly diverging orthovoltage x-ray minibeams
(referred to herein as “OXM”), which are formed by a
multi-aperture collimator positioned on the surface of a
subject’s skin, to form an effective beam of therapeutic
radiation at a predetermined tissue depth for treating a
targeted tumoror other abnormality, while sparing the skin
and a substantial portion of the tissue proximalto the target
from radiation damage. The effective beam, which may be
a substantially solid, or unsegmented beam, is formed by the
merging of the x-ray minibeams. The method utilizes the
slight divergence of the minibeams emerging from the
multiple apertures, which is due primarily to the relatively
large,finite, x-ray source spot size comparedto the relatively
small source-to-collimator distance. The depth at which the
effective beam of therapeutic radiation is formed is adjusted
by proper selection of source size, aperture size (which
determines the size of each minibeam at the skin), and
source-to-collimator distance.
An effective beam of therapeutic radiation refers to a
beam having a dose profile (perpendicular to the x-ray
beams) at a particular tissue depth across which the dose
level required to have a therapeutic effect is maintained. The
minibeams of the present disclosure merge sufficiently to
form the effective beam of therapeutic radiation. If there are
any discernible “valleys”in the profile as a result of forming
the effective beam by merging of the minibeams, the valley
dosein the effective beam of therapeutic radiation muststill
be high enough to correspondto a therapeutic radiation dose.
An effective beam of therapeutic radiation having no mea-
surable peak-valley “pattern,” or having only a small modu-
lation or peak-valley dose ratio (PVDR) of 1.10 (10%
modulation) or less, is referred to herein as a “solid” beam
of therapeutic radiation.
The term “collimator”is sometimes used interchangeably
herein with “multi-aperture collimator”to refer to the multi-
aperture collimator (which may be a multi-slit collimator)
used to form the orthovoltage minibeamsat the surface of
the skin of a subject. The multi-aperture collimator should
not be confused with a beam-shaping collimator, also known
in the art as a “multi-leaf collimator,” which may also be
used to shape the orthovoltage x-ray beam of the present
disclosure to conform to the overall shape of the target. The
multi-leaf collimator is preferably positioned to shape the
orthovoltage x-ray beam before the beam is segmented into
minibeams by the multi-aperture collimator.
The term “target” used herein refers to the tissue that is
targeted to receive a therapeutic dose ofradiation. The target
encompasses the tumoror other targeted abnormality, for
example, an epileptic lesion or epileptogenic foci, and may
also include an immediate margin oftissue surrounding the
target tumor or abnormality. One of skill in the art will
understand how to select the amount of surrounding tissue
included in the target to insure that all tumor cells, for
example, that may have spread to the immediate tissue
surrounding of the tumorare exposed. For other abnormali-
ties, the margin included in the volumedefined by the target
may be extremely small, and may be based primarily on the
system’s accuracy in targeting the volumeofinterest.
“Tissue depth” is generally used to indicate a subcutane-
ous depth.
“Proximal” is used herein to indicate a location down-
stream of the x-ray source and multi-aperture collimator, but
upstream ofthe target, i.e., located on the side of the target
closest to the x-ray source.
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“Distal” is used herein to indicate a location downstream
of the target, i.e., located on the side of the target away from
the x-ray source.
The orthovoltage x-ray minibeams emerging from the
multi-aperture collimator of the present disclosure are
slightly diverging, largely due to the penumbra effect. This
results from the relatively large focal spot size (e.g., 3 to 5
mm) of the orthovoltage x-ray source compared to the
relatively small source-to-collimator distance (20 to 45 cm).
The expected amount of divergence may be estimated
through calculations, and is based uponthe x-ray source size
(for example, the focal spot size formed on the anode of an
orthovoltage x-ray tube) and the distance between the x-ray
source (focal spot) and multi-aperture collimator.
Using the geometric estimates of the divergence of the
minibeams, other parameters of the system, as described
further herein, can be varied to deliver an effective beam of
therapeutic radiation to the target by sufficient merging of
adjacent minibeams. In preferred embodiments, parameters
are optimized such that the minibeams mergesufficiently to
form a solid, or substantially solid, effective beam of thera-
peutic radiation proximalto the edge ofthe target.
Asone ofskill in the art will appreciate, while the tissue
depth at which the minibeams will merge sufficiently to
provide an effective beam, which may, in embodiments, be
a solid beam, of therapeutic radiation can be calculated,
phantom targets such as water, or chromographic film, are
also preferably used to calibrate and tweak the system before
administering any treatment.
Referring to FIG. 2A through 2C, an embodimentof a
system 50 for implementing the methods of the present
disclosure for delivering an effective beam of therapeutic
orthovoltage x-ray radiation to a target 76 includes an
orthovoltage x-ray tube 60 and a multi-aperture collimator
70 for placing in close proximity to, or in preferred embodi-
ments, on the surface of, the skin 72 of a patient. In
embodiments, a multi-leaf collimator 77 is also positioned
between the x-ray tube 60 and the multi-aperture collimator
70 for shaping the beam emerging from the tube 60 to
conform to the overall shape of the target. Referring to FIG.
2A,the multi-aperture collimator 70, which is aligned within
the trajectory of the x-ray beam, may be touching the
patient’s skin, and slightly pushing against the skin 72.
For targets in the chest and the abdomen that move
extensively with the breathing motion, pushing the multi-
aperture collimator hard against the skin completely immo-
bilizes the skin and advantageously creates pressure that
helps immobilizethetissue to limit possible beam smearing
with the tissue movement, particularly for tissue within the
critical first centimeter and possibly further from the skin.
The smearing of the dose pattern of minibeams at deeper
tissue depths will not be as critical, since the minibeamswill
be broadening andtypically beginning to merge within a few
centimeters of tissue depth.
In embodiments, any blurring of the minibeam array dose
pattern because of the breathing movementofthe patient’s
body can be minimized by aligning the direction of the
incident minibeams so that the beams are perpendicular to
the surface of the body being treated, or parallel to the lines
of displacement of the body tissues being treated, within up
to +15°.
Referring still to FIG. 2A, the target 76 encompasses a
tumor 75 or other targeted abnormality, for example, an
epileptic lesion or epileptogenic foci, and also includes an
immediate margin of tissue surrounding the target tumor or
abnormality. In tumor therapy, typically a 5-mm margin is






that the margin is selected to cover for the uncertainties
involved in radiation therapy to insure that the entire tumor
is treated at the full dose. Such uncertainties come from,
inter alia, tumor imaging, tumorpositioning in the beam,
dosimetric calculation, and the diffuse edge of the tumor.
Referring to FIG. 2B, the orthovoltage x-ray tube 60 may
be constructed by any suitable meansin the art. In embodi-
ments, the tube 60 includes a cathode 62, which expels and
focuses electrons onto the surface 64 of an anode 66 formed
ofan appropriate target material, such as tungsten. The x-ray
source 68 for generating the orthovoltage x-rays in this
embodimentis a focal “spot” 68 (which can bealso be in the
form of a line depending on the construction of the tube 60)
formed on the anode surface 64. Referring to FIG. 2C, as
well as FIG. 2A, the x-ray source, or focal spot 68, is
characterized by an x-ray source (focal spot) size 74 defining
an area that emits orthovoltage x-rays.
In embodiments, the system 50 also includes beam hard-
ening filters 65 appropriately positioned in the path of the
x-ray beam generated by the anode.
In embodiments, the orthovoltage tubes of the present
disclosure are between about 100 kVp and 500 kVp. In
particular embodiments of the system and method of the
present disclosure, the x-rays are produced by orthovoltage
tubes of higher kVp, for example, between about 250 kVp
to about 500 kVp, and preferably, between about 300 kVp
and about 500 kVp.
In additional embodiments, the x-ray tubes of the present
disclosure may have up to 30 mA current, and preferably at
least 25 mA current.
The beam hardening filters in embodiments are copper
filters of one to several millimeters of thickness, selected to
preferably eliminate most of the low-energy end of the
spectrum. As a result, hard and penetrating beams such as
with ~4 cm orlarger tissue HVL are produced. Such beam
energies are adequate to treat many types of tumors located
at different depths, including those of the breast, the head-
and-neck, the brain, and certain tumors of the chest and
abdomen.
Referring still to FIG. 2A and FIG.2B, the system 50 may
also include a translation apparatus 78 for changing a source
to collimator distance 80 between the location of the focal
spot 68 and the multi-aperture collimator 70. While the
translation apparatus 78 as shown can translate the x-ray
tube 60 closer to, or further from the patient, in other
embodiments, the translation apparatus may instead be
associated with the device or gantry on which the patient is
positioned. Additional degrees of freedom are also prefer-
ably provided on the gantry (not shown), and/or on the
system, for correctly positioning the patient sothat the target
76 is accurately positioned within the trajectory of radiation
produced by the x-ray tube.
The x-ray tube, multi-aperture collimator, and patient are
positioned such that the target 76 is within the trajectory of
the orthovoltage x-rays emitted from the focal spot 68.
Spatially distinct, and slightly diverging x-ray minibeams 90
are formed on the surface of the skin as a result of the
orthovoltage x-rays impinging on the multi-aperture colli-
mator 70.
Referring to FIG. 2D, to accommodate the thickness of
the multi-aperture Gncluding multi-slit) collimators of the
disclosure, and the divergence of the minibeams, in embodi-
ments, the collimator 70' as shown in FIG. 2D maybeflared,
such that an output width 81 is sufficiently larger than the
input width 79 of each aperture or slit to avoid any inter-
ference of the minibeam with the walls of the collimator.
US 10,124,194 B2
11
In embodiments, the multi-aperture collimator 70 may be
a multi-aperture plate 92 with round apertures, such as that
shown in FIG. 3A, which may beflared like the collimator
70' shown in FIG. 2D, and which segments the x-ray beam
into a minibeam array 90 of nearly parallel, slightly diverg-
ing pencil-like beams. In other embodiments, the collimator
70 is a multi-slit collimator 94, such as that shown in FIG.
3B, which mayalso be flared like the collimator 70' shown
in FIG. 2D, and which segments the x-ray beam into a
minibeam array 90 of slightly diverging planar beams. The
minibeams are of sub-millimeter width, e.g., diameter 96
(pencil beams) or thickness 98 (planar beams), and are
separated by a center-to-center spacing 97.
The multi-aperture collimators of the present disclosure
may be heavy-metal collimators, comprised of a material
such as tungsten. In embodiments, the heavy-metal collima-
tors have a thickness of between about 5 to about 20 mm.
Such relatively thin multi-aperture collimators for use with
orthovoltage x-rays in accordance with the present disclo-
sure can be made, for example, of a plurality of thin
tungsten-alloy blades with spacers between them, held by a
rigid frame. In other embodiments, the tungsten multi-
aperture collimator can be made of wire cuts in a tungsten
alloy plate.
In embodiments, an array of pencil beams may be con-
figured to conform to the shape ofthe source spot size on the
anode, even without a beam-shaping, or multi-leaf, collima-
tor. In embodiments, the dose distribution produced by the
array of pencil minibeams penetrating the subject as a
function of depth in tissue will have a nearly cylindrical
uniformity.
In embodiments, pencil beams may havea cross-section
that is round, like those formed by the multi-aperture col-
limator of FIG. 3A. In other embodiments, the pencil beams
may be formed by multi-aperture collimators having ellip-
tical, square, rectangular, or polygonal apertures, or config-
ured in any other useful shape for forming the arrays.
It is noted that while planar beams may provide a less
uniform dose distribution, they can provide a larger yield of
beam throughput, particularly for oval or elongate-shaped
focal spots.
In embodiments, for planar, e.g., narrow and elongated,
minibeams, the shape of the focal spot 68 is oval or
elongated. This allows conformity between the shape of the
incident beams and the pattern of planar minibeams to be
produced. In further embodiments, the collimator has a
pattern of planarslits, such as those in FIG. 3B, and they are
aligned with the direction of the elongated length of the spot
size. This combination will produce both a high throughput
of the beam through the multi-aperture collimator and a
uniformity of dose distribution produced by the minibeams
as a function of the depth in the tissue.
In the system and method of orthovoltage x-ray radiation
therapy of the present disclosure, each of the minibeamsin
the spatially distinct array of minibeams produced by the
multi-aperture collimator 70 at the skin preferably has the
same width and center-to-center spacing. The width (e.g.,
diameter or thickness) of each of the minibeamspreferably
has a value chosen between about 0.1 mm and about 0.6 mm,
preferably, about 0.3 mm.
The minibeams are spaced regularly and closely together
by a center-to-center distance, which may be chosen, for
example, from a value ranging between about 0.1 and about
1.0 mm inclusive, depending on the minibeam width, depth
of the target and other factors described further herein.
In embodiments, the center-to-center distance between














0.5 mm and about 1.6 mm, depending on the minibeam
width, depth of the target and other factors described further
herein.
This submillimeter size of the segmented minibeams
within the non-target tissue (proximalto thetarget) results in
a very large tissue-sparing effect that, while recognized for
synchrotron x-ray therapy using parallel (non-diverging)
minibeam arrays, as described, for example, in U.S. Pat. No.
7,158,607 to Dilmanian,et al., is not known in thepriorart
of orthovoltage x-ray systems for radiation therapy.
As described herein, the orthovoltage x-ray tubes of the
present disclosure operate at voltages of up to 500 kVp,
preferably between about 300 kVp and about 500 kVp. This
higher voltage advantageously allows the x-ray beams to be
significantly filtered, with up to several mm ofcopper, e.g.,
to attenuate the low-energy end of the spectrum. This in turn
increases the median energy, i.e., hardens the beam,result-
ing in a significant increase in the depth of dose penetration
to the tissue of up to 8 cm or more tissue HVL.
Due to these characteristics of the x-ray tube of the
present disclosure, in combination with the multi-aperture
collimator construction and geometry, the minibeams in the
arrays generated in accordance with the present disclosure
can stay very narrow for many centimeters inside the
subject. By further adjusting the geometry of the beam
administration, the tissue depth at which the minibeams
merge is very well-controlled in accordance with the present
disclosure to allow administration of an effective beam,
which may be, in embodiments, a solid beam, of therapeutic
radiation to the target, while avoiding damage to both the
skin and the tissue proximalto the target.
Additional features and embodiments of the system of the
present disclosure are described and understood in the
details ofthe methods further described herein. Furthermore,
it is understood that any details of embodiments of the
disclosure described as elements of the system may also be
embodied in methods of the present disclosure.
Referring to FIG. 4A, an embodiment of a method 100 of
the present disclosure for delivering therapeutic radiation to
a target within a subject, while sparing the skin and, pref-
erably, substantial portions of tissue proximal to the target
from radiation damage, includes positioning, at 102, a
multi-aperture collimator, such as a heavy-metal collimator
plate, on the surface of the skin within a trajectory of
radiation produced by an orthovoltage x-ray tube. The target
is located at a known, predetermined depth as measured
from the irradiated portion of a surface of the skin of the
subject. The multi-aperture collimator is configured to gen-
erate an array of slightly diverging, spatially distinct, mini-
beams. In embodiments, the minibeams have a predeter-
mined center-center spacing, which may be from about 0.1
mm to about 1.0 mm inclusive, and a width ofbetween about
0.1 mm and about 0.6 mm inclusive. At 104, the skin is
irradiated with the array of orthovoltage x-ray minibeams
emerging from the multi-aperture collimator. The method
100 further includes, at 106, delivering an effective beam,
which may be, in embodiments, a solid beam, of therapeutic
radiation to the target. The effective beam is delivered by, at
108, controlling a tissue depth from the irradiated surface of
the skin at which adjacent orthovoltage x-ray minibeamsin
the array sufficiently merge to form the effective beam, and
while sparing, at 116, at least a substantial portion of tissue
proximalto the target. The sparing of tissue may be further
enhanced by limiting the width of the minibeams in the
proximal tissue, at 118, before they merge to form the
effective beam of therapeutic radiation, to 1.0 mm orless. In
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other embodiments, the width of the minibeamsbefore they
merge to form the effective beam of therapeutic radiation is
limited to 0.7 mm orless.
In embodiments, a depth ofthe tissue sparing in the body
can be varied anywhere from about 1 cm, when the front
edge of the tumor is close to the surface, to 40 cm in
embodiments in which the tumoris deeper.
Referring to FIG. 4B and FIG. 2B, for example, as
described further herein, in embodiments of the system and
methodof the present disclosure, the tissue depth at which
the adjacent minibeams mergesufficiently to form the effec-
tive beam is controlled by adjusting one or more parameters
of the system. For example, any one or combination of
adjustments listed in FIG. 4B may be used to control the
tissue depth at which the minibeams merge to form the
effective beam. For example, at least one of the predeter-
mined spacing 97 and the width 96, 98, between adjacent
minibeams may be adjusted, at 110, and/or a distance 80
between the focal spot 68 and the multi-aperture collimator
70 may be adjusted, at 112. In embodiments, controlling the
tissue depth at which the adjacent minibeams merge to form
the effective beam may further, or alternatively, include, at
114, adjusting a size of the focal spot 68 formed on the
anode.
Referring again to FIG. 2A, the small divergence angle of
each of the minibeams in the array 90 results from the
penumbraeffect of a relatively large source spot size 74,
which, in embodiments, may be between about 3-5 mm,
positioned a relatively short distance away from the multi-
aperture collimator 70. In embodiments, the distance
between the focal spot 68 and collimator 70 may be between
about 5 and about 20 cm.
In embodiments, magnitudes of the divergence angle of
the individual minibeamsofthe present disclosure are about
+/-10 milliradians,i.e., the minibeams form cones having a
full divergence angle of about 20 milliradians.
In reference to FIG. 2A and FIGS. 5A-5D,the minibeams
gradually merge as they travel further away from the skin
towardsthe target, i.e., to deeper tissue depths. Referring to
the simplified pictorial representation of the diverging
beams shown in FIG. 2A, a geometric calculation can be
madeto estimate the parameters for obtaining a solid beam,
for example, at a knowntissue depth, by merging of the
minibeams. The calculations are based on the divergence
angle of the minibeams as further described herein. The
actual dose profiles resulting from the increasing overlap-
ping of the minibeamsas they penetrate the tissue are best
shown, however, in actual stepwise cross-section profiles
measured as a function of depth, as shown in FIGS. 5A to
5D.
The dose profiles of FIGS. 5A to 5D were produced using
a320-kVp orthovoltage x-ray generator with a source size of
about 4 mm,a source-to-collimator distance of about 260
mm and with a multi-slit collimator configured to produce
0.3-mm minibeams with 0.7-mm beam spacing on-center.
FIG. 5A represents the dose profile of the minibeams
exiting the multi-slit collimator (tissue depth of 0 mm).
FIGS. 5B through 5D were measuredat distances of 13, 27,
and 40 mm,respectively, from the multi-slit collimator. As
described further below, the minibeams gradually lose their
tissue sparing effect at increasing depths, or increasing
distances from the multi-slit collimator, as the gaps between
them decrease, while the therapeutic efficacy across the
merging minibeams’ dose profile increases as the dose
between the minibeams (the “valley dose”) increases. The















As shown in FIG. 5A, the shape of the individual mini-
beams just emerging from the multi-slit collimator are
already somewhat bell-shaped because of the source and
collimator geometries involved. As these individual mini-
beamsbroaden with depth, the tails of the dose profiles start
partially overlapping with their neighbors, producing a
segmented pattern of “peaks and valleys” of neighboring
minibeams. The continuation of beam broadening gradually
increasesthis partial overlap, resulting in an increase in the
height of the valley and an increasingly more uniform-
looking pattern. The peak-to-valley dose ratio (PVDR)
decreases at increasing depths as the adjacent minibeams
merge. The PVDR of adjacent minibeams for each of the
depths 0 mm, 13 mm, 27 mm, and 40 mm in FIGS. 5A-5D
is about 5.9, 3.1, 1.3 and 1.03, respectively. At the depth of
40 mm, as shown in FIG. 5D, the PVDR of adjacent
minibeams is essentially unity (1.03) and the profile
resembles that of a unitary, conventionally-formed, beam.
The beam profile no longer appears segmented or modu-
lated, but instead represents a solid beam profile. Therefore,
for this example, a solid effective beam of therapeutic
radiation can be formedatleast by the timeit reaches a depth
of 40 mm.In embodimentsofthe present disclosure, a solid
effective beam of therapeutic radiation is formed from the
merging minibeams proximalto the edge ofthe target, such
as a tumor.
The following calculates the depth in the tissue at which
the minibeams would be expected to merge to form asolid,
unsegmented beam in a hypothetical simplified geometry
used to clarify the basic concept of beam broadening due to
the opening angle of each minibeam, based on the param-
eters used to generate the plots shown in FIGS. 5A to 5D.
Neglecting the 0.3-mm width of the collimator slit, the
opening angle of the minibeams comingout ofthe multi-slit
collimator will be about 0.0154 radian (4/260), that is 15.4
milliradian. Furthermore, neglecting the 4-mm source size
and the minibeam broadening effects produced by the un-
sharp edges of the source and collimator, the minibeams
broaden to a sharp 0.70 mm ata distance of about 45.4 mm
from the multi-slit collimator (0.0154 radianx45.4 mm=0.70
mm). This means that the sharp edges of the adjacent
minibeams touch each other at about 45.4 mm from the
multi-slit collimator to produce a solid beam.
The inaccuracies introduced in these calculations by
neglecting the finite size of the collimatorslit slightly affect
a) the opening angle of the minibeams, and b) for a given
opening angle, the actual broadening ofthe beam. These two
factors can be corrected for by convoluting the calculations
both angularly and laterally with the widths of the collima-
tor’s opening. The corrections not only will slightly add to
the actual width ofthe minibeamsat any given distance from
the multi-aperture collimator but also un-sharpen the edges
of the minibeamsas they pass through the tissues. Further-
more, the inaccuracies introduced by neglecting the actual
rounded shape of the source spot size, rounded edges of the
collimator, and by scattering ofthe x-rays in the subject, will
also lead to slightly wider beamsand slightly more round-
edness of their edges.
All these effects give the incident minibeamstheir “bell-
shaped” feature with extended “tails,” as seen in FIGS.
5A-5D, instead of a sharp “rectangular” shape. Asa result,
the beam-merging event results as a gradual overlapping of
the dose profiles (perpendicular to the x-ray beams) of the
adjacent minibeams with each other as shown in FIGS.
5A-5D.This also means that the merging of the minibeams
is a gradual process in which the “valley” doses gradually
rise and the “peak” doses gradually decline as neighboring
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peaks and valleys eventually reach substantially the same
height (ignoring non-uniformities due to other causes), thus
eventually producing a uniform, unsegmented, beam with a
PVDRthat is substantially equal to unity across the beam
profile.
In embodiments of the method and system of the present
disclosure, an effective beam of therapeutic radiation for
delivery to the target is formed by merging the minibeams
sufficiently to form a dose pattern (perpendicularto the x-ray
beams) wherein any residual “valleys”are still high enough
to correspond to a therapeutic radiation dose. Accordingly,
the minimum (valley) dose in the dose pattern (perpendicu-
lar to the x-ray beams) of the beam dueto the merging ofthe
minibeams will be equal to or greater than the minimum
effective therapeutic dose, so that an effective therapeutic
dose of radiation is delivered across the entire dose pattern
formed by the merging minibeams and across the corre-
sponding target area.
In embodiments, the effective beam of therapeutic radia-
tion formed by merging of the minibeamsat a particular
tissue depth has a substantially unsegmented dose pattern
that has no detectable modulation or that is characterized by
a PVDR(of neighboring minibeams) that is close to unity
and can thus be referred to as a solid beam of therapeutic
radiation. It is understood that while the PVDR may be
unity, or approximately unity, the overall beam profile across
the target will generally not be uniform due to the shape of
the source beam, as shown, for example, in FIG. 5D, which
showsa slight gradual increase in the profile from left to
right.
In other embodiments, depending on the geometry and
sharpness of the edges of the multi-aperture collimator, the
effective beam formed from the merging minibeams may
have an inherent heterogeneity of dose deposited in the
tumorin the areas where adjacent minibeams merge, which
have an additive affect (not related to the PVDR) and can
provide streaks of amplified dose that generate a concomi-
tant boost within the tumor.
In embodiments, the PVDR in the dose pattern of the
effective beam oftherapeutic radiation deliveredto the target
is no greater than 1.5.
In embodiments, the PVDR of the effective beam of
therapeutic radiation deliveredto thetarget is no greater than
about 1.3.
In additional embodiments, the PVDR of the effective
beam of therapeutic radiation delivered to the target is no
greater than about 1.2.
In embodiments, the effective beam of therapeutic radia-
tion deliveredto the target is essentially a solid beam, having
less than 1.10 PVDR, or having no detectable PVDR or
modulation corresponding to the array of minibeams that
merged to form the solid beam.
Referring again to FIG. 2A, FIGS. 5A-5D provide
examples of the actual beam doseprofiles as the minibeams
merge. In FIG. 5A, the dose profile 124 was generated at a
simulated tissue depth 115 just after the multi-aperture
collimator. FIG. 5B shows the dose profile 126 at a depth
120 of 13 mm, at which the tails of the minibeams have
begun to merge. At a further depth 121 of 27 mm, shown in
FIG. 5C, a lower PVDR 135 of about 1.3 to 1 is evident as
the valley dose rises and the resultant beam profile begins to
lose its segmented appearance. At a tissue depth 122 of 40
mm,the beam profile 130 is no longer modulated or appears
segmented (PVDR approaches unity or is undetectable—in
this case, PVDRis estimated to be about 1.03) at least across
most of the beam profile such that the adjacent minibeams














Referring to FIGS. 6A-6C and FIG. 4B, the system and
method of the present disclosure include controlling the
tissue depths at which the minibeams merge such that an
effective beam, which may bea solid beam, of therapeutic
radiation is deliveredto the target, while sparing the skin and
as muchofthe proximaltissue as possible. Any one or more
of a number of parameters may be varied to achieve this
desired result, such as: adjusting the spacing and/or width of
the apertures in the collimator; adjusting the focal spot to
collimator distance; adjusting a focal spot size of the anode.
FIGS. 6A-6C illustrate the result of varying just the source-
to-collimator distance for a particular anode and multi-
aperture collimator. The source to collimator distance 140 in
FIG.6B allowsan effective beam of therapeutic radiation to
be delivered to a tumor 143 at a predetermined tissue depth
142. Referring to FIG. 6A, increasing the source-to-colli-
matordistance 144, allows a deeper tumor 145to be treated
with an effective beam of therapeutic radiation at a deeper
predeterminedtissue depth 146. Similarly, referring to FIG.
6C, decreasing the source-to-collimator distance 148, allows
a shallower tumor 147 to be treated with an effective beam
of therapeutic radiation at a deeper predetermined tissue
depth 146. As demonstrated, the shorter source-to-collima-
tor distance increases the divergence of the individual mini-
beams, thus making them merge with each otherat a shorter
tissue depth.
Referring to FIG. 7A, in embodiments of the method of
the present disclosure, treatment planning for a patient
includes repeating the method described above and in FIGS.
4A and 4B for additional exposure directionsor trajectories
after the first exposure from trajectory 151. It will be
appreciated that the radiation formalism may be adjusted for
each ofthe trajectories 151, 152, 154 from a focal spot 156
of an orthovoltage x-ray tube, to make effective beams of
therapeutic radiation, which may be solid beams, at the
proximal side of the target 160, by adjusting either the
center-to-center spacing of apertures in the multi-aperture
collimator 162 for the subsequent exposures 152, 154, or the
distance 164 between the source 156 andthe collimator 162,
or by adjusting the spot size from the focal spot 156.
FIG. 7A shows minibeam administrations from three
shallow angles aimed at a tumor and its margin. As shown,
the merging point of the minibeams at which an effective
beam is formed does not necessarily have to occur imme-
diately before or at the edge of the target as long as it does
not produce much proximal tissue burden. As discussed
herein supra, an effective beam of therapeutic dose may be
produced slightly before the geometrically calculated merg-
ing point for forming a solid beam due to, inter alia,
radiation leakage between the minibeams.
One will appreciate that the target will generally not be
formed into any symmetrical volume. The outer shape ofthe
target onto which the x-ray radiation is projected, as well as
the thickness profile of the target to be treated, will change
based on the direction from which it is irradiated. A beam-
shaping collimator, such as a multi-leaf collimator, is pref-
erably positioned between the x-ray source and the multi-
aperture collimator and adjusted to conform to the shape of
the target as projected on a plane perpendicular to the
trajectory of x-rays. In embodiments, the multi-aperture
collimator can be continuously adjusted, preferably being
automatically and dynamically controlled using computer
processors and controllers, as the direction ofirradiation of




It is also noted that adjacent arrays can collide without
producing “star dose pattern,” i.e., a region of mixed-angle
minibeams,ifthe collision occurs after the merging points of
the arrays.
One of skill in the art will appreciate that the multiple
exposures from different directions may be administered
during a single treatment session, or in different treatment
sessions.
Referring to FIGS. 7A-7C, embodiments of the system of
the present disclosure may include a gantry 300, as known
in the prior art, to align the trajectory of radiation onto the
target. The subject being treated is positioned on a platform
302, or bed, which mayhaveatleast translational alignment
capabilities for positioning the subject in the aperture of the
gantry 300 and aligning the target within the trajectory. In
embodiments of the system of the present disclosure, the
x-ray source 304, beam-shaping collimator 306, and multi-
aperture collimator 308 are preferably mounted together as
a unit 305 (the unit 305 also having positioning elements as
described in reference to FIGS. 2A-2C for controlling the
tissue depth at which the minibeams merge). The multi-
aperture collimator and beam-shaping collimator remain
aligned on unit 305 within the trajectory of orthovoltage
x-rays emitted from the x-ray source 304, as the unit 305 is
rotated and/ortranslated relative to the target. Rotational and
translational arms or mounting platformsare provided on the
gantry, on which the unit 305 is operatively positioned, to
allow the trajectory of the x-rays to be positioned on the
target and to allow the direction from which the target is
irradiated to be changed in a step-wise, as well as in a
continuous fashion, to perform the methods described
herein.
The gantry 300 may, for example, includea tilt axis 310
and a rotatable ring 312 on which the unit 305 is mounted.
The unit 305 may be mounted to a radial translation stage
309 provided on the rotatable ring 312 for positioning the
unit 305 radially toward or away from the center of the ring
312 so that the multi-aperture collimator 308 can be posi-
tioned on or near the subject’s skin during treatment. Refer-
ring to FIG. 7A and FIG. 7C,the rotatable ring 312 may be
tilted, for example, from its nominal vertical 311 or perpen-
dicular plane relative to the horizontal platform 302 forward
or back around the axis 310, and translated via a transla-
tional stage 314 as needed (alternatively, the platform 302
may betranslated) to maintain the target within the trajec-
tory of the beam, for any angular position, such as for
trajectories 151, 152, 154 of FIG. 7A.
In embodiments, the multi-aperture collimator 162 of
FIG.7A is a multi-slit collimator. The multi-slit collimator
162 forms elongated planar minibeams,like those shown in
FIG. 3B. In FIG. 3B, a cross-section of an array of mini-
beams perpendicular to the trajectory of x-rays (the trajec-
tory extending into the plane of the paper of FIG. 3B, along
a y-axis) is shown, where the elongated length of the
minibeams, for example, minibeams 220, 221, 222, and 223
extends along the z-axis of the coordinate system of the
array. For reference, the coordinate system for the same
array of planar minibeams is shown in FIG. 7A for the
trajectory 154. In FIG. 7A,the elongated length ofthe planar
minibeams 220, 221, 222, and 223, and the slits or blades of
the multislit collimator that generates them, extend perpen-
dicularto the plane ofthe paper in FIG. 7A, along the z-axis.
Referring to FIGS. 7A-7B,for each ofthe three exposures
of FIG. 7A, the array of planar minibeams can also be
moved around the target on a continuous are scan, the
direction of the arc scan being shown in FIG. 7B, within






the array of slits shown in FIG.7A (parallel to the slits ofthe
collimator). Referring to FIG. 7C, the arcs of radiation may
be formedby rotation of the x-ray source 304 with multi-
aperture collimator 308 and preferably also beam-shaping
collimator 306 aligned thereto (e.g. unit 305) along a
direction 316 of the rotatable ring 312 to allow arc-scan of
a brain tumor, for example, from different angles. The target
is positioned at the center of thearcs.
The arcs merge to form an effective beam of therapeutic
radiation at the same depth as would a single minibeam in
the array, so that the effective beam, which maybe a solid
beam, of therapeutic radiation to the target is formed from
merging of the adjacent arcs ofradiation at the desired tissue
depth. In additional embodiments, the arc is generated in a
continuous step. Referring also to FIGS. 7A and 7B, for
example, the arcs 230 can be generated at each of a plurality
of positions 232, 234, 236 correspondingto trajectories and
directions 151, 152, 154 for generating the minibeam arrays.
Treatment can be implemented in one or more continuous
arc motions of the source in planes parallel to a multi-slit
collimator’s blades, for example.
For reference, the orientation of the cross-section of one
of the elongated planar minibeams 220 upon exiting the
multi-slit collimator 308 is also shown in FIG. 7C. The
direction of the are scan 230 keeps the arcs of radiation
formed from the minibeamsindividually separated as they
exit the multi-slit collimator 308, and allows the arcs of
radiation formed from the minibeams to mergeat the desired
tissue depth. The tissue depth at which the arcs merge is
preferably adjusted dynamically during the are scan to be
proximalto the target at all times. This can be accomplished,
for example, by continuously and automatically adjusting
the source to multi-slit collimator distance to produce the
optimal beam-merging tissue-depths.
Intensity modulation (referred to in the prior art as Inten-
sity Modulated Radiation Therapy of IMRT) can also be
performed during the arc scanning by continuously and
dynamically adjusting the beam-shaping collimator and thus
modulating the beam intensity during the are scanning to
conform the irradiation pattern to a shape ofthe target based
on the direction of the x-rays forming the arcs of radiation
relative to the target. The continuousrotating and translating
of the moving parts of the gantry, adjusting/positioning of
the leaves of the beam-shaping collimator, and adjusting of
the distance between the x-ray source and the multi-colli-
mator during the arc-scanning can be accomplished using
automatedcircuitry, processors, and controllers according to
methods known in theart.
In embodiments, the multi-aperture collimator of the
present disclosure, which is preferably a heavy-metal plate,
is easily interchangeable. An embodimentof a system of the
present disclosure may include pre-made multi-aperture
collimators, each having different center-to-center spacing
and a predeterminedaperture size of, for example, about 0.3
mm. In embodiments,the set of collimators may include one
or both of the pencil-beam type and planar-beam (multi-slit)
type, of different widths and/or different center-to-center
beam spacings. The appropriate multi-aperture collimator
can then be used to change the depth at which the minibeams
merge to produce an effective beam of therapeutic radiation
as needed for the particular depth of the target, as shown in
FIGS. 8A-8C, for example. A larger center-to-center spacing
170 between apertures in the collimator 172 of FIG. 8A is
required to produce an effective beam, which maybe a solid
beam,of effective radiation at a deep target depth 174, than
the spacing 176 of multi-aperture collimator 178 in FIG. 8B
for the smaller target depth 180. Similarly, a shallowertarget
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depth 182 can be achieved using a multi-aperture collimator
184 in FIG. 8C with even closer center-to-center spacing
186.
Many advantages are realized using the system and
method of the present disclosure over conventional MV
x-ray radiation therapies. As shown in FIG. 9, for example,
the beam energy spectrum 200 of a 320-kVp x-ray beam of
the present disclosure can be heavily filtered to increaseits
median beam energy to about 220 keV mostly through the
elimination of its low energy part. The resulting filtered
beam 202 has a Cu half value layer (HVL) of 3.8 mm, which
correspondsto a tissue HVL of about 10 cm. Comparingthis
220 keV median beam energy with x-rays produced by MV
electron linacs having an average median beam energy of
about 1.5 MeV, the orthovoltage energy is about seven times
smaller. This energy difference squarely puts the interaction
with tissues of the orthovoltage beam in the photoelectric
range, while that of the x-rays from MV linacs is in the
Compton scattering range, with all their differential attri-
butes as described above. The positive attributes of the
320-kVp x-rays of the present disclosure also include small
dose fall-off at the target’s edge, simplifying treatment
planning.
FIG. 10 provides an example of the good dose penetration
that is achieved with the present methods, allowing for
targets essentially at any depth to be effectively treated with
an effective beam, which may be asolidbeam,oftherapeutic
radiation. FIG. 10 was constructed to show a relationship
between orthovoltage x-rays’ Cu half-value layer and a
penetration depth in water for 50% dose penetration. The
depth-dose curve 208 is plotted for a 300-kVp machine
producing a spectrum with 2.45 mm Cu half-value layer. The
curve’s 50% dose occurs at a depth of 5 cm. Comparing this
data with the spectrum of the orthovoltage x-rays of the
present disclosure, as shown for example in FIG. 9, a
relationship is detected between the beams’ Cu half-value
layer (HVL) and its 50% depth dose in water, indicating 5
cm water depth for 50% dose when using a spectrum with
2.45 mm Cu HVL, and 8 cm water depth for 50% dose with
a spectrum of 3 mm Cu HVL.Accordingly, for 3.8 mm Cu
HVL, the 50% dose penetration in water will occur at a
depth of about 10 cm, which is considered to be a good dose
penetration.
Another advantage ofthe present methodis its application
to deep tumors, for example, over 5 cm deep. Whereas
conventional techniques for treatment of deep-seated tumors
often depend on the target being positioned on the down-
ward slope of the incident beam’s depth dose curve, with the
normal tissues positioned proximal to the target receiving
greater dose than the target, using the system and methods
of the present disclosure, the spacing between the mini-
beams can be adjusted so that the minibeams merge suffi-
ciently with each other to produce an effective beam, which
may be a solid beam, of therapeutic radiation near the
proximal side of the target. This will spare a substantial
portion of the normal tissue proximalto the target. FIG. 11
includes a plot drawn under the assumption that the mini-
beams begin to merge at about 5 cm depth. The lower curve
210 plots the biologically effective dose, which gradually
increasesin a transient region between about 3.5 cm to 5 cm
in approaching the minibeams’ merging point at about 5 cm,
when the tissue-sparing effect is gradually diminished.
Therefore the radiobiologically significant part of the curve
210 starts as one approaches 5-cm depth. This effect of
sparing of the proximal tissues also ameliorates to a larger















FIG. 11 also illustrates the superior confinement of the
dose of an effective solid beam produced by merging the
orthovoltage x-ray minibeamsofthe present disclosure. The
physical dose 214 produced by orthovoltage x-rays using a
300 kVp source with 3.8-mm Cu half-value layer (~8 cm
water HVL) is plotted and comparedto the biological dose
210, which is the effective tissue dose produced by an array
of 0.3-mm minibeams spaced 0.7 mm on-center before they
merge into a solid beam at ~5.2 cm tissue depth. Also for
comparison, the physical dose 212 for 10 MV x-rays, which
is the same as the biological dose for conventional MV
x-ray, is plotted in FIG. 11. The physical 214 and biological
orthovoltage dose 210 of the present disclosure and the dose
212 produced by the MV x-rays are super-imposed over the
background 215 of a 4 cm target located 5 cm from the
body’s surface. As shownin FIG.11,the biological dose 210
is much better confined to the tumor, both in the proximal
and the distal sides, than the dose 212 produced by the MV
x-rays.
Further, compared to the conventional radiation therapy
methods using MV x-rays or also gammarays, the present
method produces smaller dose to the non-targeted tissues
located distal to the target because of its lower beam energy
and also produces smaller dose to tissues located lateral to
the tumoror target than most conventional radiation tech-
niques because of the smaller lateral penumbra of the
orthovoltage x-ray beams.
To further enhance proximal tissue sparing, in embodi-
ments, the width and predetermined center-to-center spacing
of the minibeam array, and the distance between the focal
spot and the multi-aperture collimator, are chosen such that
each of the slightly diverging spatially distinct minibeams
broaden to no more than 1.0 mm, or in other embodiments
to no more than 0.7 mm,in width before they merge to form
the solid beam.
The tissue-sparing effect of arrays of sub-millimeter par-
allel, thin planes of high-energy MeV synchrotron x-rays
radiation, particularly when limited to 0.7 mm or less, was
established in the early 1990s at the National Synchrotron
Light Source (NSLS), Brookhaven National Laboratory
(BNL). However, both the use and the tissue-sparing char-
acteristics of sub-millimeter beams of orthovoltage x-rays in
radiation therapy is heretofore unknownin the prior art. The
enhancedtissue-sparing effect of minibeams of the present
disclosure, when limited to 0.7 mm orless, is caused by two
mechanisms, namely the “dose-volume effect” and the
“prompt biological repair effect.” The first effect, meaning
that the smaller the target, the larger is its dose tolerance, has
been known for many decadesandits effect is not limited to
millimeter or sub-millimeter beams.It has been the basis for
such effects as grid therapy and stereotactic radiosurgery.
The secondeffect, however,is indeed specific to beams with
sub-millimeter dimensions and has been studied for high-
energy synchrotron x-rays in recent years mostly in the
context of animal studies, in the context of the repair of
capillary blood vessels from sub-millimeter beam expo-
sures. The effect has been shown for MV x-ray to be
strongest for beams smaller or narrower than 0.7 mm. The
inventors have advantageously discovered that a combined
dose-volume and prompt biological repair effect is also
realized for orthovoltage x-ray beams smaller or narrower
than 0.7 mm of the present disclosure.
The methods of the present disclosure have particular
advantages in certain clinical applications, such as for treat-
ing radioresistant tumors located near viable radiosensitive
organs. In particular, radioresistant tumors of the head and
neck are often not very large and are not located at large
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tissue depths, but they are often located near radiosensitive
organs such as the parotid glands. For these applications,
twoattributes of the method are particularly helpful. First,
the orthovoltage x-ray minibeams have a very sharp dose
falloff, which significantly reduces the dose to the adjacent
normal tissues. Second, due to the tissue-sparing of the
method, tissues proximal to the target operate to spare such
organsas the salivary glands, particularly the parotid gland.
In fact, the minibeamscan pass through the parotid gland on
their way to the tumor located distal to them without
damaging the gland, if the gland, which is positioned
adjacent to the skin, is adequately thin to be in the space
where the incident minibeams are sufficiently small (less
than 0.7 mm)and are completely separated from (have not
merged with) their neighbors.
The present methods can also be combinedwith radiation
dose enhancement methods. For example, the lower beam
energy of the orthovoltage x-rays makes the present method
better suited and more effective than conventional MV
methods for combining with tumor dose enhancement. This
is because the orthovoltage x-ray photoelectric cross sec-
tions in the heavy elements used in contrast agents are
significantly larger than the cross-section of MeV x-rays in
those same elements. In embodiments, the methods
described herein include the administration of dose-enhanc-
ing substances to the patient to radio-sensitize a tumor or
other target. The agents may be of any suitable form,
including nanoparticles, and may be comprised of one or
more of iodine, gadolinium, gold, and platinum, with or
without the use of active targeting methods, and drugs
without or without encapsulation in liposomes or polymeric
delivery vehicles. The tumor dose enhancement factor can
be very large becauseofthe large photoelectric cross section
in those elements of x-raysin the orthovoltage energy range,
i.e., 150 to 400 keV x-rays. In comparison, the photoelectric
cross section of MeV is not very large at all.
Another advantage of the method and system of the
present disclosure is that they are usable for low cost,
durable and portable radiation therapy, requiring minimal
training by locally trained healthcare staff. The system
operation may be based on simple calibration, simple error
diagnosis, and open source look-up tables. Further, the
system may be configured to be operable in locations with
limited or no infrastructure, simply with accessto electricity,
and have smaller shielding requirements by virtue of its
lower beam energy. Accordingly, the system may be con-
figured as a portable, mobile treatment system (possibly on
a small truck) that can be used in low- and middle-income
countries (LMICs) to treat targets of the central nervous
system as well as other tumors with acceptable tissue depth,
and may be preferable to MV therapeutic systems in such
countries at least due to: a) the lower cost, probably by as
much as 5-fold; b) portability; c) ease of use for treatment
planning and operation, and d) smaller shielding require-
ments from the surrounding areas in the hospital of the
present orthovoltage minibeam system and method.
In addition, the methods of the present disclosure are
well-suited for treating thin tumors for which the relatively
steep dose attenuation in tissues can be tailored to minimize
the dose to the normaltissues located behind the tumor. An
example for such clinical applications is the treatment of
thyroid tumors.
The present methods are particularly well-suited for the
treatment of brain tumors and, particularly, pediatric brain
tumors due to their large tissue-sparing effects and low
accumulated dose compared to other methods. The brain








niques, produces more significant effects include the hip-
pocampusandthe cortex. Radiation damageto the pediatric
cortex has been related to the disturbance of the pediatric
cortex’s gliogenesis, a process producing neural progenitor
cells; these cells later differentiate to produce new oligo-
dendrocytes. Temporal lobes are another radiosensitive
structure whose radiosensitivity is also much higher in
children. Cognitive deficits can also be producedin patients,
particularly children, due to the integral brain dose, 1.e., the
accumulated dose given in the entire brain.
The physical characteristics ofboth MV x-rays and proton
beamsimpact the amountof radiation and the integral brain
dose on the hippocampus and cortex. Although the MV
x-rays have a sparing effect in the skin and other shallow
tissues that could coverpart ofthe cortex (FIG.1), their dose
distribution in the body is characterized by peaking early in
the tissues, large dose penetration, and large lateral penum-
bra, which can produce significant dose to the cortex on the
opposite side of the brain and to the temporal lobes. This
dose distribution also produces a large integral brain dose.
As for proton therapy, its lack of shallow-tissue-sparing
effect could translate to excessive dose to the cortex. As a
result, despite proton therapy’s much better dose confine-
ment to the target than the MV x-rays, it still produces
cognitive deficits in both adults and children.
Compared to conventional radiation therapy methods,
e.g., using MV x-rays, gammarays, or protons, the methods
of the present disclosure are particularly advantageous for
treatment of tumors of the brain, head and neck, brainstem,
spinal cord, spinal column and the like for numerous rea-
sons. For example, the orthovoltage minibeamsofthe pres-
ent disclosure produce smaller dose to the non-targeted
tissues located distal to the target because of their lower
beam energy, and they produce smaller dose to tissues
located lateral to the tumor or target due to their smaller
lateral penumbra, providing a tighter dose distribution. This
results in smaller accumulative dose to the brain, whilestill
maintaining tissue-sparing to the skin and both proximal and
distal tissue.
Dueto the tight dose distribution producedat the target by
the orthovoltage x-rays, particularly due to the sharp lateral
dose falloff described supra, the methods of the present
disclosure are also ideal for treating neurological targets
such as the epileptogenic foci. In contrast, the conventional
methods ofGamma-Knife andstereotactic radiosurgery with
MV x-rays produced by electron linacs produce a much
larger amountofdose in the non-targeted tissues. The results
are commonly an unacceptable amount ofedemain the brain
and unacceptable late radiation damage to the non-targeted
brain. On the basis of the dosimetric advantages of the
present methods over those employing high energy x-rays,
the present methods provide a much moreeffective treat-
ment for epilepsy than the conventional radiosurgery meth-
ods. The estimated factor of two in dose saving to the
non-targeted tissues that would result with the use of ortho-
voltage x-ray minibeam treatment in accordance with the
present methods is significant in increasing the method’s
efficacy by allowing the use of higher target doses and in
reducing the edema and brain damage produced in the
non-targeted brain.
The present methods can be used, for example, to treat
focal epilepsy by producing radiation damage, including
tissue necrosis, to the epileptogenic foci, with less damage
to the surrounding brain compared to the method practiced
today with MV x rays. The methodcanalso be usedto treat
general epilepsy by produced radiation damage, including
tissue necrosis, in certain brain structures.
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In embodiments, methods further include applying the
orthovoltage x-ray minibeam treatment of the present dis-
closure to the treatment of epilepsy, tumors including brain
tumors, e.g., pediatric brain tumors, and tumorsof the head
and neck, brainstem, spinal cord, and spinal column.
While the disclosure has been particularly shown and
described with reference to specific embodiments,it should
be apparent to those skilled in the art that the foregoing is
illustrative only and not limiting, having been presented by
way of example only. Well-known functions or construc-
tions are not described in detail to avoid obscuring the
present disclosure in unnecessary detail. Various changes in
form and detail may be made therein without departing from
the spirit and scope of the disclosure. Therefore, numerous
other embodiments are contemplated as falling within the
scope of the present invention as defined by the accompa-
nying claims and equivalents thereto.
Whatis claimed is:
1. Amethodfor delivering therapeutic radiation to a target
within a subject, wherein the target is located at a predeter-
mined depth, the predetermined depth being measured from
an irradiated portion of a surface of the skin of the subject,
the method comprising:
positioning a multi-aperture collimator within a trajectory
of radiation produced by an x-ray source generating
orthovoltage x-rays, the trajectory of orthovoltage
x-rays being directed at the target, the multi-aperture
collimator positioned and configured to generate an
array of minibeams on the surface of the skin compris-
ing slightly diverging spatially distinct minibeams hav-
ing a predetermined center-center spacing between
adjacent minibeams, and wherein a width of each
minibeam is between about 0.1 mm and about 0.6 mm;
irradiating the surface of the skin with the array of
minibeams; and
delivering an effective beam of therapeutic radiation to
the target, said delivering including controlling a tissue
depth from the irradiated surface of the skin at which
the adjacent minibeams in the array merge sufficiently
to form the effective beam of therapeutic radiation.
2. The method of claim 1, wherein the step of controlling
includes forming the effective beam proximalto the target.
3. The method of claim 1, wherein controlling the tissue
depth at which the adjacent minibeams mergesufficiently to
form the effective beam includes adjusting at least one of the
predetermined center-to-center spacing, the width, and a
distance between the x-ray source and the multi-aperture
collimator.
4. The method ofclaim 1, wherein delivering the effective
beam of therapeutic radiation further includes sparing irra-
diated tissue proximal to the target from radiation damage,
the tissue depth also correspondingto a tissue sparing depth.
5. The method of claim 1, further including limiting the
width of the minibeams to be between about 0.25 mm and
about 0.35 mm.
6. The method of claim 1, wherein the multi-aperture
collimator is further configured such that the array of
minibeams is a two-dimensional array of pencil minibeams,
the width corresponding to a diameter of each pencil mini-
beam.
7. The method of claim 6, wherein a cross-sectional
profile of each pencil minibeam is one of a round,elliptical,
square, rectangular, and polygonal shape.
8. The method of claim 1, wherein the multi-aperture
collimator is a multi-slit collimator configured with elon-
gated slits such that the array of minibeams is an array of








9. The method of claim 8, the width corresponding to a
thickness of each planar minibeam, the method further
including limiting the width of each planar minibeam to a
range of between about 0.25 mm to about 0.35 mm.
10. The method of claim 8, wherein the x-ray source has
an elongated shape, the method further including aligning
the elongated slits of the multi-slit collimator with the
elongated shape of the x-ray source.
11. The method of claim 1, wherein controlling the tissue
depth at which the adjacent minibeams merge sufficiently to
form the effective beam includes adjusting a size ofthe x-ray
source from which the orthovoltage x-rays are generated.
12. The method of claim 4, including varying the tissue
depth from about 1 cm to about 10 cm,the tissue depth being
based on a predetermined depth of the target from the
surface of the skin.
13. The methodof claim 1, including operating the x-ray
tube in a range between about 100 kVp and about 500 kVp.
14. The method of claim 1, wherein the multi-aperture
collimator includes a multi-aperture, heavy-metal plate.
15. The method of claim 1, wherein controlling the tissue
depth includes selecting the width, the predetermined cen-
ter-to-center spacing, and the distance between the x-ray
source and the multi-aperture collimator such that each of
the slightly diverging spatially distinct minitbeams broaden
to less than 1.0 mm in width before they merge to form the
effective beam.
16. The methodofclaim 1, the method further comprising
changing an angular position of the x-ray source and the
trajectory of orthovoltage x-rays generated therefrom rela-
tive to the target such that the target is irradiated from a
different direction, and repeating the positioning, the irradi-
ating and the delivering step for the different direction and
for irradiating a different portion of the skin with the array
ofminibeamsgenerated by the multi-aperture collimator, the
delivering step being repeated to deliver the effective beam
of therapeutic radiation to the target from the different
direction.
17. The method of claim 16, further comprising, for each
angular position, adjusting a beam-shaping collimator posi-
tioned proximal to the multi-aperture array to conform a
shapeofthe effective beam to a shape ofthe target based on
the direction of the trajectory relative to the target.
18. The method of claim 1, the irradiating step further
comprising generating an arc of radiation around the target
from each of the minibeamsin the array, the delivering step
including merging adjacent arcs of radiation at the tissue
depth to form the effective beam of therapeutic radiation.
19. The method of claim 18, wherein the minibeams are
planar minibeams formed from elongatedslits of a multi-slit
collimator, each of the arcs of radiation being generated
from the minibeams by rotating the x-ray source together
with the multi-slit collimator, such that the arcs are gener-
ated aroundthe target in planesparallel to the elongatedslits
of the multi-slit collimator.
20. The method of claim 18, further comprising adjusting
a shape and an intensity of a source beam comprising the
orthovoltage x-rays generated by the x-ray source to con-
form the effective beam of therapeutic radiation to a shape
of the target based on a direction from which the effective
beam irradiates the target, the method further comprising
continuously adjusting the distance between the x-ray source
and the multi-aperture collimator to maintain the tissue
depth, at which the arcs formed from the minibeams merge




21. The methodofclaim 1, the method further comprising
administering dose-enhancing agents to the subject prior to
the irradiating step to radio-sensitize the target.
22. The method of claim 21, wherein the agents include
one or more ofiodine, gadolinium, gold, and platinum.
23. The method of claim 21, wherein the agents are
encapsulated in one of liposomes or polymeric delivery
vehicles.
24. The method of claim 1, wherein the target encom-
passes one of a tumor and an epileptogenic foci.
25. A system for delivering therapeutic radiation to a
target volume within a subject, wherein the target is located
at a predetermined depth, the predetermined depth being
measured from an irradiated portion of the skin of the
subject, the system comprising:
an X-ray source generating orthovoltage x-rays; and
a multi-aperture collimator, the multi-aperture collimator
being configured for positioning on or near the skin and
within a trajectory of the orthovoltage x-rays generated
from the x-ray source, the trajectory of orthovoltage
x-rays being directed at the target, the multi-aperture
collimator comprising an array of apertures having a
width of between about 0.1 mm and about 0.6 mm and
a predetermined center-center spacing to generate an
array of slightly diverging spatially distinct minibeams
of the orthovoltage x-rays at the skin,
wherein the width and the predetermined center-center
spacing of the multi-aperture collimator, a size of the
X-ray source, and a distance between the x-ray source
and the multi-aperture collimator are configured to
deliver an effective beam of therapeutic radiation to the
target, the effective beam being formed by sufficient
merging of the adjacent minibeamsin the array proxi-
mal to the target.
26. The system of claim 25, wherein the width, the
predetermined center-center spacing, the size and the dis-
tance are configured to form the effective beam of thera-
peutic radiation proximalto the target.
27. The system of claim 25, wherein the multi-aperture
collimator is removably interchangeable, the system further
comprising a set of multi-aperture collimators configured
with predefined aperture widths and shapes and predefined
center-center spacings.
28. The system of claim 25, wherein the system is
portable and configured to be transported on and operated
from a mobile platform.
29. The system of claim 25, wherein the width of the
multi-aperture collimator is between about 0.25 mm and
about 0.35 mm.
30. The system of claim 25, wherein the multi-aperture
collimator is further configured such that the array of
minibeams is a two-dimensional array of pencil minibeams,
the width corresponding to a diameter of each pencil mini-
beam, wherein the diameteris a range ofbetween about 0.25
mm and about 0.35 mm.
31. The system of claim 30, wherein a cross-sectional
profile of each pencil minibeam is one of a round,elliptical,
square, rectangular, and polygonal shape.
32. The system of claim 25, wherein the multi-aperture
collimator is a multi-slit collimator configured with elon-
gated slits such that the array of minibeams is an array of
narrow and elongated planar minibeams.
33. The system of claim 25, wherein the orthovoltage
x-ray tube operates in a range between about 100 kVp and
about 500 kVp.
34. The system of claim 25, wherein the multi-aperture












35. The system of claim 25, wherein the width, the
predetermined center-to-center spacing, and the distance
between the x-ray source and the multi-aperture collimator
are configured such that each of the slightly diverging
spatially distinct minibeams broadento less than 1.0 mm in
width before merging to form the effective beam of thera-
peutic radiation.
36. The system of claim 25, further comprising a beam-
shaping collimator positioned within the trajectory of x-rays
and proximal to the multi-aperture collimator, the beam-
shaping collimator configured to be adjustable to conform
the effective beam of therapeutic radiation to a shape and
size of the target.
37. The system of claim 36, further comprising a rotatable
and translatable gantry on which the x-ray source, the
beam-shaping collimator and the multi-aperture collimator
are mounted, the gantry being positioned and configured to
be rotatable around a horizontal platform on which a subject
being treated is located, the gantry being configured to
position the target in the trajectory of the orthovoltage
x-rays, wherein the gantry is further configuredto tilt around
a vertical axis to the platform to change a direction from
which the target is irradiated with the effective beam of
therapeutic radiation, and to rotate around a longitudinal
axis of the horizontal platform to generate arcs of radiation
from each of the minibeams.
38. The system of claim 37, the system further configured
to continuously adjust the beam-shaping collimator to con-
form the effective beam to the shape and size of the target
based on the direction of irradiation as the gantry is tilted
and rotated, and to continuously adjust the distance between
the x-ray source and the multi-aperture collimator to main-
tain the tissue depth at which the effective beam is formed
to be proximal to the target.
39. A method for delivering therapeutic radiation to a
target within a subject, wherein the target is located at a
predetermined depth, the predetermined depth being mea-
sured from an irradiated portion of a surface of the skin of
the subject, the method comprising:
positioning a multi-aperture collimator within a trajectory
of orthovoltage x-rays generated by an orthovoltage
x-ray source, the trajectory of orthovoltage x-rays
being directed at the target, the multi-aperture collima-
tor positioned and configured to generate an array of
minibeams on the surface of the skin comprising
slightly diverging spatially distinct minibeams having a
predetermined width and a predetermined center-center
spacing between adjacent minibeams;
irradiating the surface of the skin with arcs of radiation
formed from the array ofminibeams,irradiating further
comprising generating the arcs of radiation around the
target from the minibeamsin the array; and
delivering an effective beam of therapeutic radiation to
the target, said delivering including controlling a tissue
depth from the irradiated surface of the skin at which
adjacent arcs of radiation formed from the adjacent
minibeams in the array merge to form the effective
beam of therapeutic radiation.
40. The methodof claim 39, including limiting the width
of the minibeamsto be between about 0.1 mm and about 0.6
mm.
41. The methodof claim 39, wherein the minibeamsare
planar minibeams formed from elongatedslits of a multi-slit
collimator, each of the arcs of radiation being generated
from the minibeams by rotating the x-ray source together
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with the multi-slit collimator, such that the arcs are gener-
ated aroundthe target in planesparallel to the elongatedslits
of the multi-slit collimator.
42. The methodof claim 39, further comprising adjusting
a shape andanintensity of the effective beam of therapeutic
radiation to conform to a shape of the target based on a
direction from which the beam irradiates the target.
43. The method of claim 42, further comprising continu-
ously adjusting the distance between the orthovoltage x-ray
source and the multi-aperture collimator to maintain the
tissue depth, at which the minibeams forming the arcs of
radiation merge sufficiently to form the effective beam, to be
proximalto the target.
* * * * *
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